Episode summary
HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus
Summary
Hims & Hers was punished after a rough earnings report that combined a surprise quarterly loss, a revenue miss, and weaker-than-expected guidance. The stock was down about 13.5% in morning trading and nearly 40% year to date, reversing the gains it had picked up after the Eli Lilly agreement to sell Zepbound and founjaro on its platform.
The report showed a loss of 14 cents a share versus expectations for 6 cents of profit, while revenue came in at $890.4 million, up 49% year over year but still below estimates. Subscriber count rose 13% to about 2.79 million, and revenue per average subscriber increased 30% to $105, but the market focused on the misses and the narrowed outlook. For the fourth quarter, HIMS guided to revenue of $875 million to $895 million and adjusted EBITDA of $70 million to $90 million.
The guest argued the reaction was harsh, but said the setup reflects a stock that has been “taken out to the woodshed.” He said $20 looks like major support and suggested a December put-spread trade to collect premium with defined risk. Longer term, he expects Hims & Hers to keep growing, but thinks the era of double-digit growth may be behind it.
Key takeaways
- The host said Hims & Hers was hit by a lethal combination of a surprise loss, a guidance cut and light sales.
- Revenue of $890.4 million rose 49% year over year, but still missed expectations by about $3 million.
- Fourth-quarter guidance of $875 million to $895 million in revenue and $70 million to $90 million in adjusted EBITDA came in below Street expectations.
- The guest said $20 looks like major support and favored a December put spread to express a range-bound view.
- The guest expects Hims & Hers to remain a solid grower, but thinks years of double-digit growth may be behind it.
Notable quotes
“it was a lethal combination for him. Now we're down 13.5% continuing the drop off that we saw in after hours trade for him and hers”
“They missed on revenue. They missed on subscriptions. They missed on earnings with that surprise loss”
“this is a stock that, as you alluded to, is basically been, you know, just taken out to the woodshed”
“I think the growth days uh of having uh doubledigit growth may be behind him but solid growth going forward at least for the future”
Topics
- hims earnings
- telehealth guidance
- revenue growth
- options trading
- stock selloff
Companies and tickers mentioned
- HIMS
- Hims & Hers
Watch the episode
Watch “HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus” on YouTube
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Schwab Network
-
Jensen Huang Weighs Return as NVDA CEO; Risks & Rewards in 2027 CapEx Trade -
KG: "Shocked" by October Retail Sales; AI Chips Struggle as NVDA Drags -
NVDA Influence Beyond Tech: How Earnings Move VIX, Other Sectors -
The Big 3: SHOP, TMUS, S -
NVDA Earnings, Tighter AI Chip Restrictions to Test SPX Bulls -
How NVDA Earnings Will Move Wall Street; U.S. Tightens AI Chip Exports
Schwab Network, this episode and its artwork belong to their owners. Octagon is not affiliated with the show; this page is an independent summary.